

pCODR Informational Webinar for Pharmaceutical Manufacturers

December 22, 2011

Hello,

The pan-Canadian Oncology Drug Review (pCODR) is a newly established evidence-based cancer drug review process, designed to bring consistency and clarity to the assessment of cancer drugs by looking at clinical evidence, cost-effectiveness and patient perspectives. The information that results from this process will be used to provide evidence-based recommendations to provinces and territories to guide their drug funding decisions.

In September and October we held information sessions for pharmaceutical manufacturers. For those who were unable to attend, we are now inviting pharmaceutical manufacturers to participate in an informational webinar on **January 17, 2012 from 3:00 p.m. to 4:30 p.m. (EST)**.

The objectives of the session are to:

1. provide an overview of the pCODR process
2. review manufacturer participation during the review process
3. highlight key steps in preparing a submission for pCODR review

We hope you will be able to join us at this informational webinar. The contributions of pharmaceutical manufacturers have been invaluable in shaping the pCODR process. Please confirm your attendance at the information session via e-mail: rsvp@pcodr.ca by January 13, 2012.